Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET

Company Participants

Temre Johnson - SD, IR

Mitchell Gold - Executive Chairman, CEO

Stanford Peng - President, Head of R&D

Andrew Sandler - CMO

Paul Rickey - CFO

Operator

Welcome to the Alpine Immune Sciences Third Quarter Earnings Call. Currently all participants are in a listen-only mode. As a reminder, this event is being recorded.

I would now like to introduce Temre Johnson, Senior Director of Investor Relations and Corporate Communications at Alpine.

Ms. Johnson, I will now turn the call over to you.

Temre Johnson

Thank you, operator. Good afternoon and thank you for joining us. With me on today's call are Dr. Mitchell Gold, Executive Chairman and Chief Executive Officer; Dr. Stanford Peng, President and Head of R&D; Dr. Andrew Sandler, Chief Medical Officer; Paul Rickey, Chief Financial Officer; and Dr. Remy Durand, Chief Business Officer.

Before I turn the call over to Mitch, I would like to remind you that we will making forward-looking statements during the course of today's call. I encourage you to refer to the most recent SEC filings regarding the risk factors associated with the statements.

Mitch, please go ahead.

Mitchell Gold

Thank you, Temre. This quarter mark several important milestones at Alpine, starting with our inaugural R&D Day in September, followed by presentations and multiple scientific meetings over the last several months, but we shard promising data that supports the best-in-class potential for our lead programs ALPN-303. We are now operationalizing, a near-term broad development plan for ALPN-303 in multiple indications with the most profitable studies to begin in a renal basket, as well as the hematology basket was anticipated data from the studies by the end of this year.

And quarterly based on data from the RUBY-1 study, we plan to move forward with a convenient dosing schedule once every four weeks and best in class profiles of inhibiting both APRIL and BAFF simultaneously. The further accelerate development is outlined three across multiple indications, we recently completed a successful and oversubscribed $113 million follow on offering, bringing additional top tier investors and extending our cash runway through the end of 2025.

This additional capital will fund key catalysts for ALPN-303 with initial data by the end of next year, actually enabling the initiation of pivotal or accelerated approval studies in certain indications. Following the termination of enrollment in the ALPN-202 clinical studies last month, Alpine is now focus squarely on driving value from an immunology and inflammation activities, including our collaborations with AbbVie and Horizon.